RLF-TD011 Investigator-Initiated Trial Results and RLF-OD032 Progress Update

Geneva, Switzerland / August 30, 2024 / Relief Therapeutics Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY)

Financial Update and Corporate Outlook

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company dedicated to advancing treatment options for select specialty, unmet, and rare diseases, recently disclosed its financial results for the half-year ended June 30, 2024. The company also shared key information about its development programs and strategic efforts.

As part of the updates, Relief highlighted RLF-TD011, an investigational hypochlorous acid topical spray for epidermolysis bullosa (EB), and RLF-OD032, a novel liquid formulation of sapropterin dihydrochloride for phenylketonuria (PKU) management.

The eagerly awaited investigator-initiated trial results for RLF-TD011 regarding EB wound treatment are expected in the coming weeks. This development is significant for patients suffering from EB, a rare genetic disorder characterized by fragile skin that easily blisters and forms wounds. The potential success of RLF-TD011 could offer a promising therapeutic option for these patients.

On the other hand, RLF-OD032’s pilot pharmacokinetic (PK) study continues to progress well, with a potential new drug application (NDA) filing anticipated by mid- to late 2025. PKU is a metabolic disorder that affects the body’s ability to metabolize the amino acid phenylalanine, leading to cognitive and developmental issues if untreated. The advancement of RLF-OD032 represents a step forward in providing an effective treatment solution for individuals with PKU.

Notably, Relief’s streamlined operations and CHF 15.1 million cash reserves are expected to provide funding support at least until 2026, ensuring the continuity of the company’s research and development efforts. This financial stability is crucial for sustaining the progress of key projects like RLF-TD011 and RLF-OD032.

How Will This Impact Me?

If you are a patient suffering from epidermolysis bullosa or phenylketonuria, the updates on RLF-TD011 and RLF-OD032 offer hope for potential new treatment options in the near future. These innovative therapies have the potential to improve your quality of life and provide better disease management strategies.

How Will This Impact the World?

The advancements in EB wound treatment and PKU management through RLF-TD011 and RLF-OD032 could have a broader global impact by addressing unmet medical needs in rare disease communities. These developments represent progress towards delivering innovative solutions for challenging health conditions and improving healthcare outcomes worldwide.

Conclusion

RELIEF THERAPEUTICS’ ongoing efforts in developing novel treatments for epidermolysis bullosa and phenylketonuria demonstrate their commitment to addressing unmet medical needs and improving patient outcomes. The anticipated trial results and progress updates on RLF-TD011 and RLF-OD032 signify promising developments in the field of rare disease therapeutics, bringing hope to individuals and communities affected by these conditions.